Filing Flows › Cytek Biosciences (CTKB) › Q2 2026 › vs Q1 2026
Cytek Biosciences (CTKB) Q2 2026 vs Q1 2026 (quarter over quarter)
Cytek Biosciences's revenue rose $4.0M (+9%) from $44.1M in Q1 2026 to $48.1M in Q2 2026. The biggest changes: Product +$3.8M (+13%); Service +$228K (+1%).
Cytek Biosciences, Q2 2026: revenue $48.1M (+6% year over year), operating margin -23.7%, net loss $12.2M, operating cash flow $1.4M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Product | $32.6M | $28.8M | $3.8M | +13% |
| Service | $15.6M | $15.4M | $228K | +1% |
| Revenue | $48.1M | $44.1M | $4.0M | +9% |
| Net loss | $12.2M | $18.9M | −$6.7M | -36% |
| Costs & expenses | $60.3M | $64.1M | −$3.8M | -6% |
| Operating costs | $59.5M | $62.6M | −$3.1M | -5% |
| Interest & other, net | $243K | −$1.1M | $1.3M | — |
| Income tax | $515K | $1.5M | −$978K | -66% |
| Cost of revenue | $19.8M | $22.9M | −$3.1M | -13% |
| Research & development | $9.7M | $9.6M | $137K | +1% |
| Sales & marketing | $13.2M | $11.6M | $1.5M | +13% |
| General & admin | $16.8M | $18.5M | −$1.6M | -9% |
| Operating cash sources | $13.5M | $16.1M | −$2.6M | -16% |
| Depreciation & amortization | $2.0M | $1.9M | $144K | +8% |
| Share-based compensation | $5.3M | $4.9M | $478K | +10% |
| Working capital & other | $6.2M | $9.4M | −$3.2M | -34% |
| Net loss absorbed | $12.2M | $18.9M | −$6.7M | -36% |
| Operating cash flow | $1.4M | −$2.7M | $4.1M | — |
| Capital expenditures | $2.2M | $2.2M | $48K | +2% |
| Negative free cash flow (OCF − capex) | $849K | $4.9M | −$4.1M | -83% |
Questions
How much did Cytek Biosciences's revenue grow quarter over quarter in Q2 2026?
Cytek Biosciences's revenue rose $4.0M (+9%) from $44.1M in Q1 2026 to $48.1M in Q2 2026.
What drove Cytek Biosciences's revenue change in Q2 2026?
Product +$3.8M (+13%); Service +$228K (+1%).